glioblastoma

A research alliance between Penn Medicine and Intel aggregated data from 6,314 glioblastoma (GBM) patients at 71 sites across six continents over three years. The study made use of federated learning – a distributed machine learning (ML) approach – to facilitate the identification of malignant brain tumors without compromising patient privacy. The research led to…

Black Diamond Therapeutics (Nasdaq: BDTX) has announced that it has dosed the first patient in the Phase 1 study focused on BDTX-1535. BDTX-1535 is a MasterKey inhibitor of epidermal growth factor receptor (EGFR) to potentially treat non-small cell lung cancer (NSCLC) and glioblastoma (GBM). Cambridge, Massachusetts–based Black Diamond believes BDTX-1535 holds significant potential for EGFR-mutant…

The cell and gene therapy company Mustang Bio (Nasdaq:MBIO) will initiate a Phase 1 clinical trial combining CAR T cells and oncolytic virus as a potential therapy for recurrent glioblastoma. The prognosis for glioblastoma is generally poor with approximately 40% survival in the first year following diagnosis, according to the American Association of Neurological Surgeons. The…

Ivy Brain Tumor Center and its partner Sonalasense have announced positive initial results in a first-in-human Phase 0/1 clinical trial involving recurrent glioblastoma patients. Sonalasense has developed a sonodynamic therapy (SDT) that pairs low-intensity ultrasound with chemotherapeutic agents known as sonosensitizers. The therapy is noninvasive. Data from the trial indicate that SDT swiftly causes targeted…

The emerging biopharmaceutical company Global Cancer Technology (GCT; San Diego) is developing a novel x-ray–activated modality for drug delivery to treat glioblastoma, which remains stubbornly difficult to treat. GCT has a licensing agreement with the University of California, San Diego (UCSD) for a drug delivery platform that unites a nanocrystal to a prodrug that can be…